Sentences with phrase «with urothelial»
Researchers at The Johns Hopkins Kimmel Cancer Center have developed a test for urine, gathered during a routine procedure, to detect DNA mutations identified with urothelial cancers.
https://www.sciencedaily.com/ Not exact matches
AA is implicated in multiple cancer types, sometimes with very high mutational burdens, especially in upper tract urothelial cancers (UTUCs).
The patients all had advanced urothelial cancer that had already been treated with platinum - based chemotherapy.
Of 56 patients with upper tract urothelial cancer, 75 percent tested positive using UroSEEK, including 79 percent of those with noninvasive tumors.
UroSEEK uses urine samples to seek out mutations in 11 genes or the presence of abnormal numbers of chromosomes that would indicate the presence of DNA associated with bladder cancer or upper tract urothelial cancer (UTUC).
A Phase III, Multicenter, Randomized, Placebo - Controlled Study of Atezolizumab (ANTI − PD - L1 Antibody) as Monotherapy and in Combination with Platinum - Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma
A Randomized, Double - Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First - line Chemotherapy in Patients with Metastatic Urothelial Cancer
Alterations to DDR genes were associated with improved outcomes in patients with metastatic urothelial carcinoma who were treated with immunotherapy.
An Open Label, Multicenter, Single Arm Phase II Pilot Study to Evaluate the Efficacy and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK - 228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract whose Tumors Harbor a TSC1 and / or a TSC2 Mutation
The designation is specifically for patients with locally advanced or metastatic urothelial cancer who have previously been treated with immune checkpoint inhibitors.
April 4, 2016 Precision medicine brings new hope to those with advanced urothelial cancer Five of six patients with advanced metastatic urothelial cancer and at least one of two specific genetic abnormalities, responded to treatment with afatinib, which was approved in 2013 by the Food and Drug Administration for patients with lung cancer, researchers report online in the Journal of Clinical Oncology.
Participants have been asked to take part in this research study because they have metastatic or surgically unresectable urothelial cancer with FGF / FGFR alterations.
The main purpose of this study is to assess how metastatic or surgically unresectable urothelial carcinoma with FGF / FGFR alterations responds to treatment with the study drug, INCB054828.
We are also examining how gene expression changes caused by chromatin modifier mutations interact with other commonly mutated pathways in urothelial cancers such as RTK - RAS - RAF and PI3K - AKT - MTOR to influence therapeutic response and resistance.
No expansion cohort in pancreatic cancer is being conducted, but phase II expansions are now ongoing in patients with NSCLC, SCCHN, urothelial carcinoma, melanoma, gastric or gastroesophageal junction cancer, and triple - negative breast cancer.